CAT catches a change artist

Cambridge Antibody Technology Group plc has defied conventional wisdom by choosing a new CEO with no experience in moving drugs through the clinic to market. Instead, the antibody company last week named Peter Chambre, who was COO at Celera Genomics Group, because of his expertise in helping companies make the transition from one stage of development to another.

"Both the board and senior company management were

Read the full 656 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE